

Turning molecules into medicines



CORPORATE OVERVIEW

Kashiv Pharma is an emerging pharmaceutical research and drug delivery company focusing on developing innovative technologies, improved medicines, and life cycle management products. We create products with meaningful clinical differentiation and a compelling value proposition for patients, physicians, and payers. Kashiv partners with established pharmaceutical companies to commercialize its products at their appropriate stage of development by offering a novel, value-added product proposition.

LEADERSHIP

The company's technical and business executives are highly talented, industry-changing experts. Each has extensive experience in analytics, product development, commercialization, and business development gained at prominent pharmaceutical companies

TECHNOLOGY PLATFORMS

Kashiv has developed several novel and proprietary technology platforms including:

Abuse Deterrent Overdose Protection Technology (ADOPT™):

Advanced abuse deterrent technologies based on physical/chemical barriers to prevent manipulation of the dosage form to resist intravenous, intranasal, and multiple pill abuse. Our first product candidate has entered clinical trials with several candidates in preclinical development.

Gastric Retention System (GRS):

A controlled drug delivery system for compounds with a narrow absorption window in the upper gastro-intestinal tract due to poor solubility, stability, or permeability. The benefits are continuous delivery for up to once-daily dosing without food effects and reducing adverse side effects associated with wide fluctuations in the plasma concentration profile. The lead product candidate is in preclinical development for the treatment of a debilitating neurological disease.

BIOMAXX®

Formulation technologies based on amorphous, nano, and lipids to maximize the bioavailability of poorly soluble and/or highly impermeable drugs to improve therapeutic performance. Our lead oral drug candidate is an injection to oral switch in preclinical development for the treatment of cancer.

FACILITIES

Kashiv operates at a premier research and development laboratories in Bridgewater, New Jersey—the heart of East Coast Pharma territory. The FDA-registered site fully complies with state, OSHA, GLP and GMP Standards and is equipped with all in-house utilities and controls, as well as the latest equipment and facilities to handle potent compounds.

ABOUT KASHIV:

- Established in October 2010
- Focused on innovative drug delivery systems and specialty drug products
- Staff of 110 employees including 45 Ph.D. scientists
- Distinguished executive team lead by Dr. Navnit Shah, Chief Scientific Officer/President, and Pavan Handa, Chief Business Officer/Executive Vice President
- Housed in a 150,000 sq. ft. state-of-the-art R&D and manufacturing facility
- Center of Excellence for pre-formulation, characterization, novel formulation platforms and complex product research
- Cutting edge infrastructure for product development and manufacturing operations
- Accomplished scientific program led by a highly qualified technical team consisting of well known, preminent experts from industry
- Ideal strategic partner for drug development, life cycle management, and commercialization

KASHIV PHARMA, LLC • 995 ROUTE 202/206 • BRIDGEWATER, NJ 08807

908-895-1520 • KASHIV PHARMA.COM